Method for treating insulin resistance

• US 5,561,165 A
• Filed: 12/01/1994
• Issued: 10/01/1996
• Est. Priority Date: 12/01/1993
• Status: Expired due to Term

• Current Assignee: Diamedica Inc.
• Original Assignee: University of Manitoba
• Inventors: Zhang, Y. Luke, Lautt, W. Wayne
• Primary Examiner(s): Rollins, John W.
• Application Number:
  US08/347,884
• Time in Patent Office: 670 Days
• Field of Search: 514/527, 514/557, 514/667, 514/866
• US Class Current: 514/667
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/221 with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• CPC Class Codes: A61K 31/27 of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine

Abstract

A method is provided for increasing insulin responsiveness and improving glucose tolerance in a mammal comprising administration of an effective amount of a cholinergic agonist; pharmaceutical compositions are also provided.

Claims

1. A method for increasing insulin responsiveness and improving glucose tolerance in a mammal in which insulin responsiveness and glucose tolerance are impaired comprising administering to the mammal an effective amount of a cholinergic agonist.

2. A method in accordance with claim 1 wherein the mammal is a human patient suffering from non-insulin dependent diabetes mellitus.

3. A method in accordance with claim 2 wherein the cholinergic agonist is administered orally.

4. A method in accordance with claim 3 wherein the cholinergic agonist is a muscarinic agonist.

5. A method in accordance with claim 2 wherein the cholinergic agonist is acetylcholine.

6. A method in accordance with claim 2 wherein the cholinergic agonist is methacholine or bethanechol.

7. A method in accordance with claim 1 wherein the mammal is a human patient with liver disease.

8. A method in accordance with claim 7 wherein the cholinergic agonist is acetylcholine.

9. A method in accordance with claim 7 wherein the cholinergic agonist is methacholine or bethanechol.

10. A method in accordance with claim 1 wherein the cholinergic agonist is selected from the group consisting of acetylcholine, methacholine and bethanechol.

11. A method for reducing insulin resistance in a mammal comprising administering to the mammal an effective amount of a cholinergic agonist.

12. A method in accordance with claim 11 wherein the mammal is a human patient suffering from non-insulin dependent diabetes mellitus.

13. A method in accordance with claim 11 wherein the mammal is a human patient with liver disease.

14. A method in accordance with claim 11 wherein the mammal is a human patient with chronic bile duct ligation.

15. A method in accordance with claim 11 wherein the cholinergic agonist is administered orally.

16. A method in accordance with claim 11 wherein the cholinergic agonist is selected from the group consisting of acetylcholine, methacholine and bethanechol.

17. A method in accordance with claim 11 wherein the cholinergic agonist is acetylcholine.

18. A method in accordance with claim 11 wherein the cholinergic agonist is methacholine or bethanechol.